Douglas C. Canfield

Mr. Canfield is the founder and President of Canfield Scientific, Inc., the world’s leading provider of optical imaging and specialized clinical imaging and analysis solutions for dermatologists and plastic surgeons. Canfield Scientific specializes in photographic documentation to help demonstrate drug efficacy in clinical drug trials worldwide. Mr. Canfield pioneered the use of specialized devices in medical photography and has developed a wide range of innovative solutions for research and practice. Canfield’s patented technology includes multi-spectral and multi-modal 2D and 3D image capture systems, digital asset management, aesthetic simulation, and applications for detection, measurement and analysis for various skin conditions. These technologies have contributed to the development of numerous treatments and procedures and has significantly advanced the use of optical imaging in both clinical research and practice. Mr. Canfield received his degree in Business Administration from Rutgers University.

Frederick Beddingfield III, M.D., Ph.D

Dr. Beddingfield is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals until it was acquired by Allergan. Frederick worked at Allergan for 10 years where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Dr. Beddingfield has led four successful FDA advisor committees. Since completing his training, he has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. He completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. Dr. Beddingfield is a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum.

John Doux, M.D., MBA

Dr. Doux obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women’s Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He had an active clinical practice for seventeen years and remains board certified in dermatology. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare. Dr. Doux is a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum.

Neal Walker, D.O., MBA

Dr. Walker co-founded Aclaris Therapeutics, Inc. and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy’s Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine. Dr. Walker is a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum.

Rox Anderson, M.D.

Dr. Anderson is Professor in Dermatology, Director of the Wellman Center for Photomedicine, and Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in dermatology. These include selective photothermolysis for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal. He also contributed to laser lithotripsy, laser angioplasty, photodynamic therapy, infrared confocal microscopy. Dr. Anderson has contributed to basic knowledge of human photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. Dr. Anderson graduated from MIT, received his M.D. degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology, and completed his residency in dermatology and research fellowships at Harvard. Dr. Anderson is a past trustee of Advancing Innovation in Dermatology, having helped co-found the organization.

Seth Orlow, M.D., Ph.D.

Dr. Orlow has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale. Dr. Orlow is a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum.

Albert Cha, M.D., Ph.D.

Dr. Cha is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO). He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is a co-founder of the annual Dermatology Summit and Dermatology Innovation Forum.

Ken Washenik, M.D., Ph.D.

Dr. Washenik is President and Chief Medical Officer of Bosley Medical Group, and former Chief Executive Officer of Aderans Research Institute, a biotechnology firm involved in researching tissue engineered hair follicle neogenesis and cellular based hair restoration. Dr. Washenik is a past President and a Board member of the North American Hair Research Society and the President of the International Society of Hair Restoration Surgery. He is also Vice Chair of the Board of Trustees of the Hair Foundation and a Board member of the Cicatricial Alopecia Research Foundation. He is a Diplomate of the American Board of Dermatology and a member of the Dermatological Society of Greater New York and the Los Angeles Metropolitan Dermatological Society. The former director of the Dermatopharmacology Unit at the New York University School of Medicine, Dr. Washenik continues to serve as a faculty member in the Department of Dermatology

Lee Zane, M.D., MAS

Dr. Zane is a board-certified dermatologist and former Senior Vice-President and Chief Medical Officer (CMO) at Anacor, where he led the successful clinical development of the novel chemical entities, tavaborole (Kerydin) and crisaborole (Eucrisa). Prior to being CMO, he had served as Anacor’s Vice President of Clinical Development from August 2008 to October 2013 and had served as Medical Director at Anacor since January 2008. From 2003 to 2007, Dr. Zane served as Assistant Professor of Clinical Dermatology at the University of California, San Francisco (UCSF), Department of Dermatology, where he was the Director of Mt. Zion Dermatology Clinical Research Unit and the Director of the Acne Specialty Practice.

Patricia S. Walker, M.D., Ph.D.

Dr. Walker is a board-certified dermatologist and industry expert specializing in the fields of medical and aesthetic dermatology. She has been in clinical practice for over 20 years, serving as Chief Medical Officer for Kythera Biopharmaceuticals, Inc., and Executive Vice President and Chief Scientific Officer for Allergan Medical Aesthetics. Dr. Walker is at the forefront in the arena of medical and aesthetic dermatology. Her work as a clinical and research & development expert has contributed substantially to the world of dermatology, particularly in the area of facial injectables. Over the past 10 years, she has led key product approvals in dermatology, including the development and approval of Tazorac®, Botox® Cosmetic, Juvederm™, Hylaform®, Captique®, LAP-BAND® and Inamed® Silicone gel-filled Breast Implants. Dr. Walker is the Executive Chairman of ClearifiRx, a dermatologist-led online platform providing personalized prescriptions to treat skin conditions.